Business
Male athletes running in big graphic space
(Getty Images)
sell your soles

On Running is widening its lead over rival shoe brand Hoka

On just reported sales up 38% on a constant currency basis, as the Swiss brand eyes Nike-level numbers.

Tom Jones, David Crowther

For those in the business of Reading Things Online, it felt like you couldn’t go more than a few weeks last summer without seeing a new piece on how upstart running shoe brands like On and Hoka had industry behemoths like Adidas, Nike, and New Balance quaking in their sneakers.

Media (and investor) hype for the two athletic shoe sellers might have subsided a little, but both brands continue to make huge strides forward as runners around the world add Clifton 10s and Cloudsurfers to their collections and workers adopt the comfort-first sneakers to return to the office in style.

Build phase

With strikingly similar origin stories — Hoka was founded in the French Alps by two athletes in 2009, while On Holding was launched by three a year later in Zurich, Switzerland — the brands’ tracks have barely diverged in the years since. In 2012, American footwear giant Deckers snapped up Hoka One One, as it was at the time, for a reported $1.1 million. On, meanwhile, signed Swiss tennis legend Roger Federer as a brand representative in 2019, giving him a 3% stake in the company, and went public two years later.

Hoka and On annual sales chart
Sherwood News

For most of the past six or so years, On and Hoka’s sales had broadly run neck and neck, with not much to split the two Europe-birthed brands. However, the former has really started to kick on in recent years, with the Swiss company reporting ~$2.6 billion in sales last year and announcing another impressive quarter yesterday, in which sales jumped 38% (currency adjusted).

The Hoka brand isn’t exactly a slouch, posting $2.2 billion in revenue for the last fiscal year, but investors’ expectations maybe got ahead of reality. Hoka notched just ~20% sales growth in its latest quarter, and Deckers’ stock has been crushed this year, dropping nearly 50%, as Hoka sales slow down in the all-important US market.

More Business

See all Business
Strive Pharmacy recently broke ground on a new facility in Mesa, Arizona. (Strive Pharmacy)

Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution of prescription drugs.

business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.